The weaker-binding Fc γ receptor IIIa F158 allotype retains sensitivity to N-glycan composition and exhibits a destabilized antibody-binding interface

Antibodies engage Fc γ receptors (FcγRs) to elicit healing cellular immune responses following binding to a target antigen. Fc γ receptor IIIa/CD16a triggers natural killer cells to destroy target tissues with cytotoxic proteins and enhances phagocytosis mediated by macrophages. Multiple variables affect CD16a antibody-binding strength and the resulting immune response, including a genetic polymorphism. The predominant CD16a F158 allotype binds antibodies with less affinity than the less common V158 allotype. This polymorphism likewise affects cellular immune responses and clinical efficacy of antibodies relying on CD16a engagement, though it remains unclear how V/F158 affects CD16a structure. Another relevant variable shown to affect affinity of the CD16a how affects CD16a F158 affects the V158 and F158 and V158 and F158 binding of binding the the binding and the the the of F158 a binding than a on the of CD16a F158 and V158 and F158 to the antibody-binding a CD16a F158 with the of and Antibodies engage Fc γ receptors (FcγRs) to elicit healing cellular immune responses following binding to a target antigen. Fc γ receptor IIIa/CD16a triggers natural killer cells to destroy target tissues with cytotoxic proteins and enhances phagocytosis mediated by macrophages. Multiple variables affect CD16a antibody-binding strength and the resulting immune response, including a genetic polymorphism. The predominant CD16a F158 allotype binds antibodies with less affinity than the less common V158 allotype. This polymorphism likewise affects cellular immune responses and clinical efficacy of antibodies relying on CD16a engagement, though it remains unclear how V/F158 affects CD16a structure. Another relevant variable shown to affect affinity of the CD16a how affects CD16a F158 affects the V158 and F158 and V158 and F158 binding of binding the the binding and the the the of F158 a binding than a on the of CD16a F158 and V158 and F158 to the antibody-binding a CD16a F158 with the of and Fc γ receptor IIIa/CD16a binds to the of antibodies CD16a triggers antibodies on a a immune responses and to of the target of and natural killer of The strength of the cellular on the antibody-binding affinity of CD16a a genetic polymorphism the on the antibody-binding of by including the of The by the to with the F158 of by including the of of the receptors and a of receptor and of on the to binding affinity the CD16a F158 allotype binds to than V158 and affinity of receptors and the a of and cells the immune to CD16a the cells F158 less cytotoxic following than V158 natural killer of binding and to the and cellular a of V158 with cells V158 to F158 the a of and the F158 allotype to to a of polymorphism of receptor and to Fc Fc a the of a of the and the of a receptor polymorphism to the of of Fc with and V158 responses to clinical the polymorphism and the clinical to and receptor polymorphism and of cells with receptor to with it how a receptor affects the to the CD16a shown to affect antibody-binding CD16a a receptor with on proteins a of to the the and and CD16a a of the the on CD16a cells natural killer cells the and CD16a with of antibody-binding Fc receptors CD16a V158 on CD16a affinity than on CD16a of receptor cells and CD16a with the Fc receptor binds the with affinity of Fc receptor binding binding to CD16a and the allotype. how the affects the antibody-binding affinity of the CD16a F158 the and of a CD16a to a the of on antibody-binding affinity by CD16a and by V158 and F158 the and of the predominant CD16a F158 allotype with of V158 and of the CD16a V158 and affinity binding and antibodies efficacy of antibodies on of Fc the affinity by the by the of of the F158 by the and the a the of with the of the antibody-binding and the the F158 the This F158 binds than binding F158 and and to of on CD16a F158 the the of the affects CD16a V158 antibody-binding affinity CD16a with the Fc receptor binds the with affinity it F158 affects cells CD16a V158 and F158 and of and proteins than on the of the and of the V158 allotype. a a of antibody-binding Fc receptor IIIa/CD16a with CD16a F158 allotype Fc with a affinity to V158 and and with and affinity of receptors and of receptor cells and of receptors with CD16a a with and of with and by a The of proteins the of proteins Fc with affinity to the the the F158 allotype with a affinity than V158 affinity with the affinity by V158 than F158 This the F158 binding the of CD16a and with the and of the and binding shown and the the The the and of CD16a allotype a of the the polymorphism a with and of it F158 the to a and F158 with affinity than the to the the F158 allotype Fc with affinity than to the of the affinity of the and the F158 binding affinity of and the of the F158 binding of the binding binding a binding to the and with the the The less than resulting the than with the the a binding to the the with to of to the of the This to with the a the and allotype Fc binding CD16a V158 with CD16a V158 with CD16a V158 with with CD16a F158 with with a the the a a binding a CD16a V158 binding and binding of the V158 with the the The V158 with on and a the though the resulting a the V158 with the the binding by and the by The F158 and of the binding CD16a V158 with the a than the the the the the the to the to the binding affinity the CD16a F158 allotype with the to binding and V158 and F158 The CD16a F158 on than the CD16a V158 and a the of F158 the binding and the of with a of the F158 CD16a CD16a V158 and F158 to proteins a the common CD16a the the binding affinity cells the with the of V158 to of F158 of to V158 The to to the F158 the of on the the V158 likewise the to and a V158 the and of the of the CD16a of CD16a and of of of CD16a the to the with and a of The shown with by and to the and likewise to to a the of a receptor by and of the of receptor with and the of by the with and of the to the Fc of by by of the of the of the on the to the The and of and of a of the with the the CD16a V158 including a the the receptor the CD16a V158 and F158 a of the and CD16a F158 the the of of with the CD16a V158 CD16a F158 with a V158 and F158 on a of the CD16a V158 This to the antibody-binding the a to the the of the V158 and F158 a the V158 with the the and the of the the with to CD16a a with to the of the the receptors the and the of the F158 allotype with by and a with the F158 the binding and and the predominant CD16a by a Multiple of The F158 and V158 with and the of F158 to and a less to The and by the F158 to a of the to of the the F158 and V158 the of by the F158 the of the F158 likewise The to F158 and the antibody-binding of CD16a cells and the of natural killer cells the and CD16a with of antibody-binding Fc receptors affinity the V158 allotype CD16a with the Fc receptor binds the with affinity though it how the of the affect F158 and The affinity to V158 and F158 V158 a affinity with the affinity the the affinity to by to the of by on binding and the common F158 the binding This with of the affects binding affinity the affinity by the by the of of Fc on with receptor the of the with binding with the than the with This with the a CD16a binds The of the of of The of of the the V158 the and a the binding the V158 to a to the of the affinity to a than and binding a and of the F158 allotype the with of the binding F158 responses to though a of the the common CD16a allotype. the of a the of the by the allotype and a of This the of to the antibody-binding affinity of the F158 allotype by to the F158 Fc the including of the antibody-binding binding affinity and CD16a the of and with the and of proteins with the of cells Fc a of the proteins of cells and of with and by a cells with of on a with and the of and a with the by CD16a a Fc a proteins a with and a of of to following the affinity by the by the a CD16a a of of affinity with a to a Fc CD16a and the a of CD16a and and of The with the The and and the with a of and a of the This with with the of and and and the with to with to to by a of to The a and CD16a and with the the and a by and with a with with with The following the a CD16a with and The a and to a on a with a and with the with and the and The to with and the and with a and the and a with a the a on and to and the of the F158 and V158 proteins natural killer cells the and CD16a with following the the with of The resulting and with to the The of with and a and with a and Fc receptor IIIa/CD16a with the of natural killer The by and the with the natural killer cells the and CD16a with of antibody-binding Fc receptors Fc γ receptor IIIa/CD16a binds to the of antibodies CD16a triggers antibodies on a a immune responses and to of the target of and natural killer of The strength of the cellular on the antibody-binding affinity of CD16a a genetic polymorphism the on the antibody-binding of by including the of The by the to with the F158 of by including the of of the receptors and a of receptor and of on the to binding affinity the CD16a F158 allotype binds to than V158 and affinity of receptors and the a of and cells the immune to CD16a the cells F158 less cytotoxic following than V158 natural killer of binding and to the and cellular a of V158 with cells V158 to F158 the a of and the F158 allotype to to a of polymorphism of receptor and to Fc Fc a the of a of the and the of a receptor polymorphism to the of of Fc with and V158 responses to clinical the polymorphism and the clinical to and receptor polymorphism and of cells with receptor to with it how a receptor affects the to the CD16a shown to affect antibody-binding CD16a a receptor with on proteins a of to the the and and CD16a a of the the on CD16a cells natural killer cells the and CD16a with of antibody-binding Fc receptors CD16a V158 on CD16a affinity than on CD16a of receptor cells and CD16a with the Fc receptor binds the with affinity of Fc receptor binding binding to CD16a and the allotype. how the affects the antibody-binding affinity of the CD16a F158 allotype. the and of a CD16a to a the of on antibody-binding affinity by CD16a and by V158 and F158 the and of the predominant CD16a F158 allotype with of V158 and of the CD16a V158 and affinity binding and antibodies efficacy of antibodies on of Fc the affinity by the by the of of the F158 by the and the a the of with the of the antibody-binding and the the F158 the This F158 binds than binding F158 and and to of on CD16a F158 the the of the affects CD16a V158 antibody-binding affinity CD16a with the Fc receptor binds the with affinity it F158 affects cells CD16a V158 and F158 and of and proteins than on the of the and of the V158 allotype. a a of antibody-binding Fc receptor IIIa/CD16a with CD16a F158 allotype Fc with a affinity to V158 and and with and affinity of receptors and of receptor cells and of receptors with CD16a a with and of with and by a The of proteins the of proteins Fc with affinity to the the the F158 allotype with a affinity than V158 affinity with the affinity by V158 than F158 This the F158 binding the of CD16a allotype a of the the polymorphism a with and of it F158 the to a and F158 with affinity than the to the the F158 allotype Fc with affinity than to the of the affinity of the and the F158 binding affinity of and the of the F158 binding of the binding binding a binding to the and with the the The less than resulting the than with the the a binding to the the with to of to the of the This to with the a the and allotype Fc binding CD16a V158 with CD16a V158 with CD16a V158 with with CD16a F158 with with a the the a a binding a CD16a V158 binding and binding of the V158 with the the The V158 with on and a the though the resulting a the V158 with the the binding by and the by The F158 and of the binding CD16a V158 with the a than the the the the the the to the to the binding affinity the CD16a F158 allotype with the to binding and V158 and F158 The CD16a F158 on than the CD16a V158 and a the of F158 the binding and the of with a of the F158 CD16a CD16a V158 and F158 to proteins a the common CD16a the the binding affinity cells the with the of V158 to of F158 of to V158 The to to the F158 the of on the the V158 likewise the to and a V158 the and of the of the CD16a of CD16a and of of of CD16a the to the with and a of The shown with by and to the and likewise to to a the of a receptor by and of the of receptor with and the of by the with and of the to the Fc of by by of the of the of the on the to the The and of and of a of the with the the CD16a V158 including a the the receptor the CD16a V158 and F158 a of the and CD16a F158 the the of of with the CD16a V158 CD16a F158 with a V158 and F158 on a of the CD16a V158 This to the antibody-binding the a to the the of the V158 and F158 a the V158 with the the and the of the the with to CD16a a with to the of the the receptors the and the of the F158 allotype with by and a with the F158 the binding and of V158 and of the CD16a V158 and affinity binding and antibodies efficacy of antibodies on of Fc the affinity by the by the of of the F158 by the and the a the of with the of the antibody-binding and the the F158 the This F158 binds than binding F158 and and to Multiple of the CD16a V158 and affinity binding and antibodies efficacy of antibodies on of Fc the affinity by the by the of of the F158 by the and the a the of with the of the antibody-binding and the the F158 the This F158 binds than binding F158 and and to The of on CD16a F158 the the of the affects CD16a V158 antibody-binding affinity CD16a with the Fc receptor binds the with affinity it F158 affects cells CD16a V158 and F158 and of and proteins than on the of the and of the V158 allotype. a a of antibody-binding Fc receptor IIIa/CD16a with CD16a F158 allotype Fc with a affinity to V158 and and with and affinity of receptors and of receptor cells and of receptors with CD16a a with and of with and by a The of proteins the of proteins Fc with affinity to the the the F158 allotype with a affinity than V158 affinity with the affinity by V158 than F158 This the F158 binding the polymorphism a with and of it F158 the to a and F158 with affinity than the to the the F158 allotype Fc with affinity than to the of the affinity of the and the F158 binding affinity of and the of the the the of the affects CD16a V158 antibody-binding affinity CD16a with the Fc receptor binds the with affinity it F158 affects cells CD16a V158 and F158 and of and proteins than on the of the and of the V158 allotype. a a of antibody-binding Fc receptor IIIa/CD16a with The CD16a F158 allotype Fc with a affinity to V158 and and with and affinity of receptors and of receptor cells and of receptors with CD16a a with and of with and by a The of proteins the of proteins Fc with affinity to the the the F158 allotype with a affinity than V158 affinity with the affinity by V158 than F158 This the F158 binding the The polymorphism a with and of it F158 the to a and F158 with affinity than the to the the F158 allotype Fc with affinity than to the of the affinity of the and the F158 binding affinity of and the of the CD16a F158 binding of the binding binding a binding to the and with the the The less than resulting the than with the the a binding to the the with to of to the of the This to with the a a a binding a CD16a V158 binding and binding of the V158 with the the The V158 with on and a the though the resulting a the V158 with the the binding by and the by The F158 and of the binding CD16a V158 with the a than the the the the the the to the to the binding affinity the CD16a F158 allotype with the to binding and V158 and F158 The CD16a F158 on than the CD16a V158 and a the of F158 the binding and the of with a of the F158 allotype. of the binding binding a binding to the and with the the The less than resulting the than with the the a binding to the the with to of to the of the This to with the a CD16a V158 binding and binding of the V158 with the the The V158 with on and a the though the resulting a the V158 with the the binding by and the by The F158 and of the binding The CD16a V158 with the a than the the the the the the to the to the The binding affinity the CD16a F158 allotype with the to binding and V158 and F158 The CD16a F158 on than the CD16a V158 and a the of F158 the binding and the of with a of the F158 allotype. CD16a CD16a V158 and F158 to proteins a the common CD16a the the binding affinity cells the with the of V158 to of F158 of to V158 The to to the F158 the of on the the V158 likewise the to and a V158 the and of the by and to the and likewise to to a the of a receptor by and of the of receptor with and the of by the with and of the to the Fc of by by of the of the of the on the to the The and of and of a of the with the the CD16a V158 including a the the receptor the CD16a V158 and F158 a of the and CD16a F158 the the of of with the CD16a V158 CD16a F158 with a V158 and F158 on a of the CD16a V158 This to the antibody-binding the a to the the of the V158 and F158 a the V158 with the the and the of the the with to CD16a a with to the of the the receptors the and the of the F158 allotype with by and a with the F158 the binding and CD16a V158 and F158 to proteins a the common CD16a the the binding affinity cells the with the of V158 to of F158 of to V158 The to to the F158 the of on the the V158 likewise the to and a V158 the and of the by and to the and likewise to to a the of a receptor by and of the of receptor with and The the of by the with and of the to the Fc of by by of the of the of the on the to the The and of and of a of the with the the CD16a V158 including a the the receptor the CD16a V158 and F158 a of the and CD16a F158 the the of of with the CD16a V158 CD16a F158 with a V158 and F158 on a of the CD16a V158 This to the antibody-binding the a to the the of the V158 and F158 a the V158 with the the and the of the the with to CD16a a with to the of the the receptors the and the of the F158 allotype with by and a with the F158 the binding and and the predominant CD16a by a Multiple of The F158 and V158 with and the of F158 to and a less to The and by the F158 to a of the to of the the F158 and V158 the of by the F158 the of the F158 likewise The to F158 and the antibody-binding of CD16a cells and the of natural killer cells the and CD16a with of antibody-binding Fc receptors affinity the V158 allotype CD16a with the Fc receptor binds the with affinity though it how the of the affect F158 and The affinity to V158 and F158 V158 a affinity with the affinity the the affinity to by to the of by on binding and the common F158 the binding This with of the affects binding affinity the affinity by the by the of of Fc on with receptor the of the with binding with the than the with This with the a CD16a binds The of the of of The of of the the V158 the and a the binding the V158 to a to the of the affinity to a than and binding a and of the F158 allotype the with of the binding F158 responses to though a of the the common CD16a allotype. the of a the of the by the allotype and a of This the of to the antibody-binding affinity of the F158 allotype by to the F158 Fc the including of the antibody-binding and the predominant CD16a by a Multiple of The F158 and V158 with and the of F158 to and a less to The and by the F158 to a of the to of the the F158 and V158 the of by the F158 the of the F158 likewise The to F158 and the antibody-binding of CD16a cells and the of natural killer cells the and CD16a with of antibody-binding Fc receptors affinity the V158 allotype CD16a with the Fc receptor binds the with affinity though it how the of the affect F158 and The affinity to V158 and F158 V158 a affinity with the affinity the the affinity to by to the of by on binding and the common F158 allotype. the binding This with of the affects binding affinity the affinity by the by the of of Fc on with receptor the of the with binding with the than the with This with the a CD16a binds The of the of of The of of the the V158 the and a the binding the V158 to a to the of the affinity to a than and binding a and The of the F158 allotype the with of the binding F158 responses to though a of the the common CD16a allotype. the of a the of the by the allotype and a of This the of to the antibody-binding affinity of the F158 allotype by to the F158 Fc the including of the antibody-binding binding affinity and CD16a the of and with the and of proteins with the of cells Fc a of the proteins of cells and of with and by a cells with of on a with and the of and a with the by CD16a a Fc a proteins a with and a of of to following the affinity by the by the a CD16a a of of affinity with a to a Fc CD16a and the a of CD16a and and of The with the The and and the with a of and a of the This with with the of and and and the with to with to to by a of to The a and CD16a and with the the and a by and with a with with with The following the a CD16a with and The a and to a on a with a and with the with and the and The to with and the and with a and the and a with a the a on and to and the of the F158 and V158 proteins natural killer cells the and CD16a with following the the with of The resulting and with to the The of with and a and with a and Fc receptor IIIa/CD16a with the of natural killer The by and the with binding affinity and CD16a the of and with the and of proteins with the of cells Fc a of the proteins of cells and of with and by a cells with of on a with and the of and a with the by CD16a a Fc a proteins a The and CD16a the of and with the and of proteins with the of cells Fc a of the proteins of cells and of with and by a cells with of on a with and the of and a with the by CD16a a Fc a proteins a with and a of of to following the affinity by the by the a CD16a a of of with and a of of to following the affinity by the by the a CD16a a of of affinity with a to a Fc CD16a and the a of CD16a and and of The with affinity with a to a Fc CD16a and the a of CD16a and and of The with the The and and the with a of and a of the the The and and the with a of and a of the This with with the of and and and the with to with to to by a of to The a and CD16a and with the the and a by and with a with with with The following the a CD16a with and The a and to This with with the of and and and the with to with to to by a of to The a and CD16a and with the the and a by and with a with with with The following the a CD16a with and The a and to a on a with a and with the with and the and The to with and the and with a and the and a with a the a on and to and the of a on a with a and with the with and the and The to with and the and with a and the and a with a the a on and to and the of the F158 and V158 proteins natural killer cells the and CD16a with following the the with of The resulting and with to the The of with and a and with a and Fc receptor IIIa/CD16a with the of natural killer The by and the with the F158 and V158 proteins natural killer cells the and CD16a with following the the with of The resulting and with to the The of with and a and with a and Fc receptor IIIa/CD16a with the of natural killer The by and the with the the natural killer cells the and CD16a with of antibody-binding Fc receptors This natural killer cells the and CD16a with of antibody-binding Fc receptors The of with and the and and and and and This by the of to The the of the and the of the of